Shanghai Pharmaceuticals Holdings ADR (SHPMY) – aksjekurser og nyheter

Shanghai Pharmaceuticals is a private-sector Chinese pharmaceutical company. The organization develops and distributes pharmaceutical products and operates in domestic and international markets. Shanghai Pharma is the largest pharmaceutical and the first A+H listed company in China to be dual-listed by Shanghai and Hong Kong Stock Exchanges. As of 2020, the company made its presence to the Global Fortune 500 list with the ranking of 473, overall and 124 among 21 other Chinese companies on the list. Shanghai Pharmaceuticals was founded in 1994 and is headquartered in Shanghai. As an investment holding company, it is actively engaged in research, manufacturing and distribution of pharmaceutical and healthcare products in China, that develops and distributes traditional Chinese and chemical drugs, chemical, biochemical and healthcare goods that are applied in various therapeutic fields, including immunoregulation and anti-cancer, immune system and digestion, cardiovascular and anti-infection, nervous system and mental disorder. Wikipedia

Om Shanghai Pharmaceuticals Holdings ADR

Administrerende direktør-

Ansatte48,6k

Grunnlagt18. jan. 1994

Hovedkontor-

Sektor-

Nettstedsphchina.com

Alle verdier i CNY	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	73,48 mrd.	68,51 mrd.	75,26 mrd.	72,21 mrd.
Varekostnad	66,03 mrd.	60,55 mrd.	67,17 mrd.	64,09 mrd.
Direkte driftskostnader	66,03 mrd.	60,55 mrd.	67,17 mrd.	64,09 mrd.
Utgifter til forskning og utvikling	556,53 mill.	824,53 mill.	468,22 mill.	502,64 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	4,70 mrd.	4,97 mrd.	4,59 mrd.	4,65 mrd.
Driftskostnader	5,58 mrd.	5,91 mrd.	5,47 mrd.	5,55 mrd.
Totale driftskostnader	71,60 mrd.	66,47 mrd.	72,63 mrd.	69,64 mrd.
Driftsinntekter	1,88 mrd.	2,04 mrd.	2,63 mrd.	2,57 mrd.
Andre ikke-operasjonelle inntekter	−84,84 mill.	−63,65 mill.	−47,88 mill.	−7,43 mill.
EBT inkludert uvanlige elementer	1,48 mrd.	1,52 mrd.	2,42 mrd.	3,21 mrd.
EBT uten uvanlige elementer	1,61 mrd.	1,44 mrd.	2,27 mrd.	3,03 mrd.
Kostnad for inntektsskatt	485,91 mill.	534,14 mill.	569,09 mill.	720,64 mill.
Faktisk avgiftssats	32,89 %	35,10 %	23,52 %	22,43 %
Andre driftskostnader	129,62 mill.	271,29 mill.	132,16 mill.	186,62 mill.
Nettoinntekt	688,20 mill.	577,49 mill.	1,42 mrd.	2,09 mrd.
Netto fortjenestemargin	0,94 %	0,84 %	1,88 %	2,89 %
Resultat per aksje	-	-	-	-
Rente- og investeringsinntekter	206,57 mill.	-	38,70 mill.	873,52 mill.
Rentekostnader	−393,02 mill.	−470,36 mill.	−347,64 mill.	−358,39 mill.
Netto rentekostnader	−186,45 mill.	−470,36 mill.	−308,94 mill.	515,13 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	2,26 mrd.	2,54 mrd.	3,12 mrd.	3,07 mrd.
Gevinst eller tap ved salg av eiendeler	39,99 mill.	−157,15 mill.	-	−179,70 mill.

Finance

Spør om hva som helst